• CLL progression <24 months since the completion of the last prior therapy.
• Constitution symptoms.
• If last prior therapy contained an anti-CD20, must have evidence of disease improvement during therapy or progression ≥ 6 months after completion.
• Must have at least one bi-dimensionally measurable lesion ≥ 2.0 cm in the longest dimension

Giliead CBCI-235

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BS-1101 (CAL-101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia

• Have a hematologic malignancy that is expected to express the CD22 antigen for which no effective standard therapy exists.
• Must have at least on bi-dimensionally measurable lesion ≥ 1.5 cm.

Genentech CBCI-210

An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia